Demographic and treatment-related characteristics of the patient sample

PatientAge (yr)/SexPathologyInitial TherapySurgery Prior to Bevacizumab Scan (mo)aPre and Post-Bevacizumab Scans (day)bPost-Bevacizumab Pathologyc
158/FGBM WHO IVXRT + TMZ; TMZ 5/28GTR, 1−31, +29
362/FGBM / WHO IVXRT + TMZ; TMZ 3/14STR, 1+−3, +112GBM/WHO IV
449/MGBM/WHO IVXRT + TMZ; TMZ 3/14STR, 1−10, +22
557/FGBM/WHO IVXRT + TMZ; TMZ 5/28, TMZ 3/14STR, 6+−13, +49GBM/WHO IV
663/FGBM/WHO IVXRT + TMZ; TMZ 5/28STR, 1−28, +46GBM/WHO IV + radiation effect
766/MGBM/WHO IVXRT + TMZ; TMZ 5/28STR, 5−2, +34GBM/WHO IV + radiation necrosis
856/MAOA/WHO IIIXRT + TMZ; TMZ 5/28RXN, 4+−15 days, +15
967/MGBM/WHO IVXRT + TMZ; TMZ 5/28GTR, 7−7, +29 days
1027/FAA/WHO IIIXRT + TMZBx, 2+−8, +16
1140/MGBM/WHO IVXRT + TMZ; TMZ 5/28STR, 5+−37, +35
1256/MGBM/WHO IVXRT + TMZ; TMZ 5/28STR, 7−49, +27
  • Note:—AOA indicates anaplastic oligoastrocytoma; AA, anaplastic astrocytoma; XRT + TMZ, radiotherapy plus adjuvant temozolomide; TMZ 5/28, temozolomide for 5 days every 28 days; TMZ 3/14, temozolomide for 3 days every 14 days; GTR, gross total resection; STR, subtotal resection; RXN, craniotomy and resection; Bx, biopsy; AGN, anaplastic glioneural neoplasm; WHO = World Health Organization.

  • a Months shown indicate the interval between the surgical event and the first scan obtained during bevacizumab treatment.

  • b Interval in days between the scan prior to bevacizumab treatment (pre-bevacizumab scan), and initiation of bevacizumab therapy, followed by the interval in days between initiation of bevacizumab therapy and first scan during bevacizumab treatment (post-bevacizumab scan).

  • c Pathology after bevacizumab therapy had started.